- Home
- BAX vs HALO Comparison
BAX vs HALO Comparison
Compare BAX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAX | HALO |
|---|---|---|
| Founded | 1931 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.8B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BAX | HALO |
|---|---|---|
| Price | $18.63 | $68.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $21.00 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 6.5M | 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.56 |
| Revenue | ★ $11,244,000,000.00 | $151,862,000.00 |
| Revenue This Year | $1.96 | $28.24 |
| Revenue Next Year | $2.22 | $12.56 |
| P/E Ratio | ★ N/A | $26.70 |
| Revenue Growth | ★ 5.72 | N/A |
| 52 Week Low | $15.73 | $47.50 |
| 52 Week High | $32.68 | $82.22 |
Technical Indicators
Market Signals| Indicator | BAX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 55.82 |
| Support Level | $17.69 | $67.94 |
| Resistance Level | $18.89 | $71.53 |
| Average True Range (ATR) | 0.58 | 1.83 |
| MACD | 0.31 | 0.66 |
| Stochastic Oscillator | 76.91 | 75.68 |
Price Performance
Historical ComparisonAbout BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.